Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: SRPT stock price vs SWK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SWK's multiple
Needs SWK P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · SWK FY 2026 (ended Jan 3, 2026). Fiscal years are not aligned.
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
STANLEY BLACK & DECKER, INC. · implied price per share
Bear
$7.40
Base
$8.70
Bull
$10.01
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
0.64x
Net debt / EBITDA
Leverage against operating earnings
0.01x
3.78x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$280.10M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
SMITH A O CORP
SRPT vs AOS
WHIRLPOOL CORP /DE/
SRPT vs WHR
NEWELL BRANDS INC.
SRPT vs NWL
Snap-on Inc
SRPT vs SNA
ILLINOIS TOOL WORKS INC
SRPT vs ITW
$934.46M
$5.81B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can materially improve margins and move toward sustainable profitability, then holding or accumulating on weakness can be justified because the stock is only slightly below SWK-implied value and still sits within its historical band; otherwise, the weak quality scores and deeply negative margins argue for caution.
SRPT’s current price of $19.28 is only 2.5% below the implied price of $19.77 based on the P/S comparison, so the valuation gap is small. The fact that SRPT and SWK both trade at 0.9x P/S suggests the market is not awarding SRPT a material multiple discount despite very different operating profiles.
Supporting Metrics
